Contact
searchSearch
HMP Global
Login

Alzheimer & Dementia Related Cognitive Disorders Topic Center

A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
From Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
rna strand
News
New Potential Drug Targets for Alzheimer Disease Identified
05/21/2025
Maria Mantas
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in...
05/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
person holding cannabis
Cannabis Use Requiring Acute Care Increases Dementia Risk
04/22/2025
Jolynn Tumolo
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older with an acute care encounter due to cannabis use had a 3.9-fold higher risk of a new dementia diagnosis within 5 years compared with the general population, according to a recent study.
People aged 45 years or older...
04/22/2025
Neurology
From Neurology
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
From Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
From Neurology

News

A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network
FDA approval stamp
News
FDA Approves Modified Titration Dosing for Donanemab-azbt to Reduce ARIA-E Incidence in Early AD
07/10/2025
Maria Mantas
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug Administration (FDA) has approved a label update for donanemab-azbt (Kisunla), Eli Lilly and Company’s monthly intravenous amyloid-targeting therapy for adults with early symptomatic Alzheimer disease (AD).
The US Food and Drug...
07/10/2025
Psych Congress Network
rna strand
News
New Potential Drug Targets for Alzheimer Disease Identified
05/21/2025
Maria Mantas
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in Nature Communications identified new potential drug targets for the treatment and prevention of Alzheimer disease (AD). 
A recently published study in...
05/21/2025
Psych Congress Network
FDA approval stamp
News
FDA Clears First Blood Test to Help Diagnose Alzheimer Disease
05/19/2025
Meagan Thistle
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the Lumipulse G pTau217/β-Amyloid 1-42 Plasma Ratio test, the first blood-based diagnostic tool intended to aid in evaluating Alzheimer disease (AD) pathology.
The FDA has approved the...
05/19/2025
Psych Congress Network
Neurons in the brain
News
Risk Factors for Late-Onset Epilepsy in Patients With Cognitive Decline Identified
04/21/2025
Jolynn Tumolo
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk factors in people with cognitive decline include Parkinson disease, early-onset dementia (before age 60), poor cognition, stroke or transient ischemic attacks, Alzheimer disease, and the APOE4 allele.
Late-onset epilepsy (LOE) risk...
04/21/2025
Neurology
A doctor and patient talk
News
Later Life Depressive Symptoms Not Linked With Amyloid Accumulation
03/04/2025
Jolynn Tumolo
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal cognition, depressive symptoms were not consistently associated with amyloid pathology. Meanwhile, depressive symptoms were associated with a reduced likelihood of amyloid pathology in older adults with mild...
In older adults with normal...
03/04/2025
Psych Congress Network
FDA building
News
FDA Approves Once-Monthly Lecanemab-irmb Dosing for Early Alzheimer Disease
01/28/2025
Meagan Thistle
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a supplemental biologics license application for lecanemab-irmb (Leqembi, Eisai Co., Ltd.; Biogen Inc.), an intravenous treatment (IV) for early Alzheimer disease (AD).
The FDA has approved a...
01/28/2025
Psych Congress Network
US FDA sign
News
Posdinemab Granted Fast Track Designation by the FDA for Early Alzheimer Disease
01/10/2025
Brionna Mendoza
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated tau-directed monoclonal antibody (mAb) being studied for the treatment of early Alzheimer disease (AD), was granted Fast Track designation by the US Food and Drug Administration (FDA).
Posdinemab, a phosphorylated...
01/10/2025
Psych Congress Network
a researcher examines MRI scans
News
Diabetes, Amyloid Pathology Linked With Progression to MCI Over 20 Years
01/02/2025
Jolynn Tumolo
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal amyloid-β concentration in cerebrospinal fluid were associated with accelerated brain atrophy and an earlier progression to mild cognitive impairment (MCI) in a cohort study.
Type 2 diabetes and an abnormal...
01/02/2025
Neurology
DNA strand
News
Pharmacogenomic Test Improves MDD Response and Remission Outcomes
09/15/2025
Jolynn Tumolo
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific weighted multigene pharmacogenomic (PGx) test significantly improved outcomes in adult patients with major depressive disorder (MDD) with at least 1 treatment failure, according to meta-analysis results.
Clinician use of a specific...
09/15/2025
Psych Congress Network
fda building sign
News
FDA Approves TMS Device for Major Depressive Disorder in Adolescents
09/11/2025
Brionna Mendoza
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug Administration (FDA) approved on Wednesday the Apollo Transcranial Magnetic Stimulation (TMS) Therapy devices for the adjunctive treatment of major depressive disorder (MDD) in adolescents.
The US Food and Drug...
09/11/2025
Psych Congress Network
cannabis plant and CBD oil
News
High Levels of THC in Cannabis Products Associated With Mental Health Risks
09/11/2025
Maria Mantas
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained high concentrations of delta-9-tetrahydrocannabinol (THC) were associated with psychosis, schizophrenia, and cannabis use disorder (CUD), according to a systematic review.
Cannabis products that contained...
09/11/2025
Psych Congress Network
child embraces mother
News
Child Depression During COVID-19 Pandemic Associated With Subsequent Maternal Depression
09/02/2025
Maria Mantas
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and 11 years during the COVID-19 pandemic was significantly associated with later maternal depression, according to longitudinal study results.
Child depression at ages 10 and...
09/02/2025
Psych Congress Network
An orange prescription container with generic pills spilling out in front of it
News
Early ADHD Drug Treatment Linked With Reduced Risk of Suicide, Substance Misuse, and Other Adverse Outcomes
08/27/2025
Jolynn Tumolo
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with attention-deficit/hyperactivity disorder (ADHD) who began drug treatment within 3 months of diagnosis had significantly reduced rates of suicidal behaviors, substance misuse, traffic accidents, and criminality.
Patients with...
08/27/2025
Psych Congress Network
An illustrated picture shows two cartoon doctors, one holding up a magnifying glass to a cartoon brain.
News
Investigational App for Negative Schizophrenia Symptoms Meets Primary Trial Endpoint
08/25/2025
Jolynn Tumolo
An investigational prescription digital therapeutic targeting negative symptoms in patients with schizophrenia met its primary endpoint in a pivotal phase 3 randomized controlled study.
An investigational prescription digital therapeutic targeting negative symptoms in patients with schizophrenia met its primary endpoint in a pivotal phase 3 randomized controlled study.
An investigational prescription...
08/25/2025
Psych Congress Network
tired man rubs eyes
News
Vulnerability to Inflammation-Related Depression Exaggerated in Older Adults With Insomnia
08/18/2025
Jolynn Tumolo
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults without insomnia, older adults with the sleep disorder experienced a 3-fold greater increase in depressed mood and depressive symptoms after exposure to an inflammatory challenge, according to study findings.
Compared with older adults...
08/18/2025
Psych Congress Network
A woman lies in bed awake due to insomnia
News
Cannabinoids Produce Worse Sleep Outcomes in Small Pilot Study
08/15/2025
Brionna Mendoza
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of tetrahydrocannabinol/cannabidiol (THC/CBD) resulted in worse sleep for study participants with insomnia.
A single dose of...
08/15/2025
Neurology
A person completes a puzzle of a profile of a head, with a piece missing from where the brain is located.
News
Alzheimer Disease Drugs Show Double the Impact in Long-Term Extension Results
08/05/2025
Jolynn Tumolo
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer disease (AD) treated with lecanemab and donanemab experienced a higher degree of reduced cognitive decline in clinical trial extension studies compared with 18-month results from the core trials.
Patients with early Alzheimer...
08/05/2025
Neurology
doctor holds clipboard of data and research
News
Limited Demographic Data Transparency Found in Evidence Supporting FDA-Authorized AI Devices for Alzheimer Treatment
07/30/2025
Maria Mantas
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited demographic data transparency in the evidence supporting FDA-authorized artificial intelligence (AI)– and machine learning (ML)–enabled medical devices for the treatment of Alzheimer disease and related dementias.
Researchers found limited...
07/30/2025
Psych Congress Network

Quizzes

quiz
Quiz
Percentage of Patients With Major or Mild Frontotemporal NCD Found With Alzheimer Disease Pathology at Autopsy
07/11/2024
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients presenting with a syndrome suggestive of major or mild frontotemporal neurocognitive disorder (NCD) are found at autopsy to have Alzheimer disease pathology, according to the DSM-5-TR?
What percentage of patients...
07/11/2024
Psych Congress Network
Why do hurricanes increase mortality risk in ADRD populations?
Quiz
Why do hurricanes increase mortality risk in ADRD populations?
04/04/2023
Do you remember this study?
Do you remember this study?
Do you remember this study?
04/04/2023
Psych Congress Network
Four pencils with their erasers spelling out "quiz."
Quiz
What strategies can individuals use to reduce their risk of Alzheimer disease?
09/28/2022
Take the quiz to test your clinical knowledge!
Take the quiz to test your clinical knowledge!
Take the quiz to test your...
09/28/2022
Psych Congress Network
Craig Chepke, MD, DFAPA
Quiz
Muscarinic Receptor-Based Options for Treatment-Resistant Schizophrenia
09/12/2025
Maria Mantas
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of this interview with Dr Chepke?
Do you remember the details of...
09/12/2025
Psych Congress Network
medication
Quiz
Test Your Knowledge: Study Results Link Non-Stimulant ADHD Therapy and Prescription Stimulant Misuse in Adolescents
09/09/2025
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about the risk of non-stimulants? Test your understanding of ADHD treatment and stimulant misuse.
What does research reveal about...
09/09/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge – Targeting Hyperactivity and Impulsivity in Adolescents: A Look at Viloxazine ER
09/04/2025
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of non-stimulants in ADHD treatment? Take this quick quiz to test your knowledge of viloxazine ER.
Think you understand the role of...
09/04/2025
Psych Congress Network
Dr Rakesh Jain
Quiz
Test Your Knowledge: Dr Rakesh Jain on Nonstimulant Treatment Options for Pediatric ADHD
09/03/2025
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the evolving landscape of non-stimulant ADHD treatments? Take this quick quiz to find out.
How well do you know the...
09/03/2025
Psych Congress Network
Wooden blocks spelling QUIZ
Quiz
Test Your Knowledge: Viloxazine ER Added to Stimulant Treatment for Pediatric ADHD Appears Safe, Effective
09/02/2025
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance stimulant therapy in pediatric ADHD? Take this quick quiz to test your knowledge.
Can viloxazine ER enhance...
09/02/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 3
Quiz
Test Your Knowledge – Navigating ADHD Care Forward: The Future of ADHD
08/27/2025
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test your knowledge on combination treatment strategies, novel mechanisms, and how emerging data is reshaping care for complex patients of all ages.
Take this quick quiz to test...
08/27/2025
Psych Congress Network
Drs Mattingly, Price, Amann Part 2
Quiz
Test Your Knowledge – Real-World Data Deep Dive: Viloxazine ER Compared With Atomoxetine for ADHD Study
08/25/2025
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER compares to atomoxetine in real-world ADHD treatment—test your knowledge with this short, expert-driven quiz.
Discover how viloxazine ER...
08/25/2025
Psych Congress Network
blocks spelling out the word "quiz"
Quiz
Initiating Clozapine in Patients With Schizophrenia
08/15/2025
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following scenarios does the American Psychiatric Association (APA) recommend initiating clozapine in patients with schizophrenia?
In which of the following...
08/15/2025
Psych Congress Network
Pharmacokinetics icon
Quiz
Test Your Knowledge – Pharmacokinetics of Viloxazine ER: What to Expect From Onset to Duration
08/12/2025
How well do you know the pharmacokinetics of viloxazine ER? Take this quiz to sharpen your clinical insight.
How well do you know the pharmacokinetics of viloxazine ER? Take this quiz to sharpen your clinical insight.
How well do you know the...
08/12/2025
Psych Congress Network
Hand blocking small red sad face buttons from large green smiling face button
Quiz
Test Your Knowledge – Viloxazine ER’s Impact on Comorbid Conditions: A Broader Approach to ADHD Management
08/12/2025
Discover how viloxazine ER is reshaping ADHD treatment—especially for patients with comorbid challenges—in this short clinical quiz.
Discover how viloxazine ER is reshaping ADHD treatment—especially for patients with comorbid challenges—in this short clinical quiz.
Discover how viloxazine ER is...
08/12/2025
Psych Congress Network

Perspectives

marc agronin md
Faculty Insights
Alzheimer Disease Prevention: Part 2
07/29/2024
Marc E. Agronin, MD
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated sequel to his 2022 blog, Marc Agronin, MD, geriatric psychiatry section editor at Psych Congress Network, offers deeper expert clinical insights on Alzheimer disease prevention.
In this highly anticipated...
07/29/2024
Psych Congress Network
Leslie Citrome, MD, MPH.
Videos
Addressing Agitation in Dementia
11/09/2023
Leslie Citrome, MD
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals living with Alzheimer disease and dementia in the United States, effective home-based strategies are crucial to prevent institutionalization.
With 7 million individuals...
11/09/2023
Psychiatry & Behavioral Health
Dr Paul Schulz
Videos
Lecanemab Considerations and Efficacy
10/16/2023
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
10/16/2023
Psych Congress Network
Dr Paul Schulz
Videos
Patient Considerations When Prescribing Lecanemab for Alzheimer Disease
09/22/2023
Paul Schulz, MD
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Schulz discusses the...
09/22/2023
Psych Congress Network
Dr Paul Schulz
Videos
Advantages and Drawbacks of Lecanemab in Alzheimer Disease Treatment
09/11/2023
Paul Schulz, MD
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the newly FDA-approved lecanemab for the treatment of AD.
Dr Paul Shulz discusses the...
09/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
Telepsychiatry Practice for Geriatric Patients
08/11/2023
Marc E. Agronin, MD
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, CMO, describes his experience treating geriatric patients via telehealth.
In this exclusive video, Psych...
08/11/2023
Psych Congress Network
Marc Agronin, MD.
Videos
What the Data Tells Us About Telepsychiatry Efficacy and Popularity
07/20/2023
Marc E. Agronin, MD
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric Psychiatry Section Editor Marc Agronin, MD, discusses the meteoric rise of telehealth in mental health care practice.
Psych Congress Network Geriatric...
07/20/2023
Psych Congress Network
Marc Agronin, MD.
Blog
Alzheimer Disease Prevention
08/30/2022
Marc E. Agronin, MD
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section Editor Mark Agronin, MD, provides expert clinical insights on reducing the risk for Alzheimer disease and delaying its onset and progression.
Psych Congress Network Section...
08/30/2022
Psych Congress Network
Douglas_Scharre_alzheimers_aducanumab
Videos
Putting Research Into Practice With Aducanumab for Alzheimer Disease
08/27/2021
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre, MD discusses his presentation “Translating Research Into Practice Everything You Need To Know About Aducanumab But Were Afraid To Ask,” which was given virtually at Neurology Week.
In this video, Douglas Scharre,...
08/27/2021
Psych Congress Network
Edward Kaftarian, MD
Videos
Billing, Reimbursement, and Maximizing Revenue for Telehealth Services
09/09/2025
Edward Kaftarian, MD
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.
In this video, Psych Congress Steering Committee Member Edward Kaftarian, MD, provides an overview of recent developments in reimbursement policies for telehealth services.
In this video, Psych Congress...
09/09/2025
Psych Congress Network
Brooke Kempf, PMHNP-BC
Videos
Shaping the Future of Schizophrenia Care With Muscarinic-Targeting Treatments
09/05/2025
Brooke Kempf, MSN, PMHNP-BC
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress Steering Committee Member Brooke Kempf, PMHNP-BC, discusses how the development of muscarinic-targeting treatments is shaping the future of schizophrenia care.
In this video, Psych Congress...
09/05/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Hypersomnolence in Individuals With Mental Illness
09/05/2025
Craig Chepke, MD, DFAPA
Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.
Craig Chepke, MD, DFAPA, discusses how sleep disorders manifest in psychiatric patients and novel treatments available for these conditions.
Craig Chepke, MD, DFAPA,...
09/05/2025
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Greg Mattingly, MD
Videos
Distinguishing Tardive Dyskinesia From Other Movement Disorders
09/04/2025
Greg Mattingly, MD
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the 2025 NP Institute, Psych Congress Co-Chair Greg Mattingly, MD, provides an insightful overview of the telltale signs that can help clinicians distinguish TD from other movement disorders.
In this video, filmed at the...
09/04/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Navigating Regulations Regarding the Prescription of Controlled Substances via Telehealth
09/03/2025
Edward Kaftarian, MD
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych Congress Elevate 2025, Steering Committee Member Edward Kaftarian, MD, walks clinicians through current and forthcoming regulations regarding the prescription of controlled substances via telehealth.
In this video, filmed at Psych...
09/03/2025
Psych Congress Network
Hara Oyedeji
Videos
Tackling Demographic Disparities in Schizophrenia Diagnosis
08/11/2025
Hara Oyedeji, APRN, PHMNP-BC, MS Ed
In this video, Psych Congress NP Institute Faculty Member Hara Oyedeji, APRN, PMHNP-BC, MSEd, discusses the demographic disparities that exist in the diagnosis of schizophrenia.
In this video, Psych Congress NP Institute Faculty Member Hara Oyedeji, APRN, PMHNP-BC, MSEd, discusses the demographic disparities that exist in the diagnosis of schizophrenia.
In this video, Psych Congress NP...
08/11/2025
Psych Congress Network
Edward Kaftarian, MD
Videos
Practical Strategies for Building Patient Rapport Via Telehealth
08/07/2025
Edward Kaftarian, MD
In this video, Edward Kaftarian, MD, discusses effective strategies for building patient rapport via telehealth.
In this video, Edward Kaftarian, MD, discusses effective strategies for building patient rapport via telehealth.
In this video, Edward Kaftarian,...
08/07/2025
Psych Congress Network
Craig Chepke, MD, DFAPA
Videos
Considerations for Incorporating Muscarinic Agonists Into Schizophrenia Treatment
08/05/2025
Craig Chepke, MD, DFAPA
Psych Congress Elevate Co-Chair and Scientific Director Craig Chepke, MD, DFAPA, shares an overview of some of the most promising clinical findings regarding muscarinic receptor activators.
Psych Congress Elevate Co-Chair and Scientific Director Craig Chepke, MD, DFAPA, shares an overview of some of the most promising clinical findings regarding muscarinic receptor activators.
Psych Congress Elevate Co-Chair...
08/05/2025
Psych Congress Network
Desiree Matthews
Videos
Anticipating Medication Interactions in Tardive Dyskinesia
08/01/2025
Desiree Matthews, PHMNP-BC
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC, Steering Committee, Psych Congress, walks clinicians through common medication interactions to be aware of as they develop treatment plans for patients with TD.
Desiree Matthews, PMHNP-BC,...
08/01/2025
Psych Congress Network

NEW FROM THE NP INSTITUTE ONLINE LEARNING HUB

andrew and julie
Rapid Refresh
Navigating Bipolar Disorder Treatment: Exploring the Role of Second-Generation Antipsychotics
04/11/2024

Featuring Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN

Featuring Andrew Penn, MS, PMHNP, and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and Julie Carbray, PhD, FPMHNP-BC, PMHCNS-BC, APRN, explore the nuanced role of second-generation antipsychotics in bipolar disorder treatment. They discuss the complexities of managing mania and depression phases and...
Andrew Penn, MS, PMHNP, and...
04/11/2024
Psych Congress NP Institute
Amber Hoberg
Rapid Refresh
Long-Acting Injectables for Adolescents With Schizophrenia and Schizoaffective Disorder
04/10/2024
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC, navigates the complexities of adolescent psychosis treatment, exploring the potential benefits and considerations of LAIs for schizophrenia and schizoaffective disorder, while emphasizing evidence-based practice for...
Amber Hoberg, PMHNP-BC,...
04/10/2024
Psych Congress NP Institute
Hoberg and Matthews
Clinical Pearls
Tolerability Testing in Long-Acting Injectable Prescriptions
04/03/2024
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for tolerability before prescribing a long-acting injectable (LAI)? Desiree Matthews, PMHNP-BC, and Amber Hoberg, MSN, APRN, PMHNP-BC, offer their clinical insight.
Do clinicians need to test for...
04/03/2024
Psych Congress NP Institute

Sign Up

Psych Congress Network Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use